Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-TNF Clear all

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more

Conditions: Crohn's Disease
Interventions: Adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 43
States / cities: La Jolla, California • San Francisco, California • Arvada, Colorado + 33 more

Conditions: Psoriatic Arthritis
Interventions: Human anti-TNF monoclonal antibody/adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Juvenile Idiopathic Arthritis
Interventions: CNTO 148 (Golimumab), Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more

Conditions: Stomatitis
Interventions: Etanercept, Placebo; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 16 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Greenville, South Carolina

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, etanercept; Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Rheumatoid Arthritis
Interventions: Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab; Drug · Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions: TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 2 Years to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Brivekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more

Conditions: HIV, Inflammation
Interventions: Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Axial Spondyloarthritis
Interventions: Adalimumab, Placebo, Open-label Adalimumab; Biological
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Denver, Colorado + 6 more

Conditions: Crohn's Disease
Interventions: PF-00547659; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 47
States / cities: La Jolla, California • Orange, California • Lafayette, Colorado + 21 more

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease (CD)
Interventions: Risankizumab, Ustekinumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 72
States / cities: Chandler, Arizona • Coronado, California • Irvine, California + 62 more

Conditions: Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Interventions: Anti TNF therapy including infliximab, No Biologics; Biological · Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 4,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2038
U.S. locations: 58
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Conditions: COVID-19
Interventions: INB03, Placebo; Drug
Lead sponsor: Inmune Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more

Conditions: Crohn's Disease
Interventions: adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 97
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Healthy
Interventions: BIIB023, Placebo; Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Crohn's Disease
Interventions: CPSI-2364 or placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Gulf War Illness, Persian Gulf Syndrome, Occupational Diseases
Interventions: Etanercept, Mifepristone; Drug
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more

Conditions: Crohn Disease
Interventions: Cimzia; Biological
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 20
States / cities: Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more

Conditions: Crohn's Disease
Interventions: Certolizumab pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Montgomery, Alabama • La Jolla, California + 46 more

Search by objective public record fields.

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

Study of Adalimumab in Patients With Axial Spondyloarthritis

A Study To Monitor Long-Term Treatment With PF-00547659

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

INB03 for the Treatment of Pulmonary Complications From COVID-19

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers

Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)

Understanding GWI: Integrative Modeling

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease